|
1
|
Zhang B, Yin Y, Hu Y, Zhang J, Bian Z,
Song M, Hua D and Huang Z: MicroRNA-204-5p inhibits gastric cancer
cell proliferation by downregulating USP47 and RAB22A. Med Oncol.
32:26452015.
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sheikh IA, Mirza Z, Ali A, Aliev G and
Ashraf GM: A proteomics based approach for the identification of
gastric cancer related markers. Curr Pharm Des. 22:804–811. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al: Global surveillance of cancer survival 1995–2009: Analysis
of individual data for 25,676,887 patients from 279
population-based registries in 67 countries (CONCORD-2). Lancet.
385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hundahl SA: Staging, stage migration, and
patterns of spread in gastric cancer. Semin Radiat Oncol.
12:141–149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomassen I, van Gestel YR, van Ramshorst
B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE and de Hingh IH:
Peritoneal carcinomatosis of gastric origin: A population-based
study on incidence, survival and risk factors. Int J Cancer.
134:622–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan MC, Balakrishnan M and Graham DY:
Gastric cancer worldwide except Japan. Gastric Cancer. Shiotani A:
Springer; Singapore: pp. 17–28. 2019, View Article : Google Scholar
|
|
10
|
Song H, Zhu J and Lu D: Molecular-targeted
first-line therapy for advanced gastric cancer. Cochrane Database
Syst Rev. 7:CD0114612016.PubMed/NCBI
|
|
11
|
Ohno T, Yokoyama Y, Aihara R, Mochiki E,
Asao T and Kuwano H: Sudden bilateral sensorineural hearing loss as
the presenting symptom of meningeal carcinomatosis of gastric
cancer: Report of a case. Surg Today. 40:561–565. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jansen EP, Saunders MP, Boot H, Oppedijk
V, Dubbelman R, Porritt B, Cats A, Stroom J, Olmos RV, Bartelink H
and Verheij M: Prospective study on late renal toxicity following
postoperative chemoradiotherapy in gastric cancer. Int J Radiat
Oncol Biol Phys. 67:781–785. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boku N: HER2-positive gastric cancer.
Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kepil N, Batur S, Sonmez Wetherilt C and
Erdamar Cetin S: Human epidermal growth factor receptor 2 (HER-2)
status evaluation in advanced gastric cancer using
immunohistochemistry versus silver in situ hybridization. Bosn J
Basic Med Sci. 17:109–113. 2017.PubMed/NCBI
|
|
15
|
Mishra S, Yadav T and Rani V: Exploring
miRNA based approaches in cancer diagnostics and therapeutics. Crit
Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, Feng J, Zhi X, Tang J, Li Z, Xu Y,
Yang L, Hu Z and Xu Z: Let-7b inhibits cell proliferation,
migration, and invasion through targeting Cthrc1 in gastric cancer.
Tumour Biol. 36:3221–3229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao
XH, Guo G, Zou QM and Xiao B: miR-30b, down-regulated in gastric
cancer, promotes apoptosis and suppresses tumor growth by targeting
plasminogen activator inhibitor-1. PLoS One. 9:e1060492014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin Y, Zhang B, Wang W, Fei B, Quan C,
Zhang J, Song M, Bian Z, Wang Q, Ni S, et al: miR-204-5p inhibits
proliferation and invasion and enhances chemotherapeutic
sensitivity of colorectal cancer cells by downregulating RAB22A.
Clin Cancer Res. 20:6187–6199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang Y, Zhang CD, Zhang C and Dai DQ:
DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor
progression and epithelial-mesenchymal transition in gastric
cancer. Gastric Cancer. 23:212–227. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang QX, Zhu YQ, Zhang H and Xiao J:
Altered miRNA expression in gastric cancer: A systematic review and
meta-analysis. Cell Physiol Biochem. 35:933–944. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shin VY and Chu KM: MiRNA as potential
biomarkers and therapeutic targets for gastric cancer. World J
Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi Y, Wang Z, Zhu X, Chen L, Ma Y, Wang
J, Yang X and Liu Z: Exosomal miR-1246 in serum as a potential
biomarker for early diagnosis of gastric cancer. Int J Clin Oncol.
25:89–99. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Sun H, Guan J, Ji T and Wang X:
Serum microRNA-381: A potential marker for early diagnosis of
gastric cancer. Yonsei Med J. 60:720–726. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Wang J, Li X, Ma J, Shi C, Zhu H,
Xi Q, Zhang J, Zhao X and Gu M: miR-204-5p suppresses cell
proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.
Biochem Biophys Res Commun. 457:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luan W, Qian Y, Ni X, Bu X, Xia Y, Wang J,
Ruan H, Ma S and Xu B: miR-204-5p acts as a tumor suppressor by
targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in
malignant melanoma. Onco Targets Ther. 10:1237–1246. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chu Y, Jiang M, Du F, Chen D, Ye T, Xu B,
Li X, Wang W, Qiu Z, Liu H, et al: miR-204-5p suppresses
hepatocellular cancer proliferation by regulating homeoprotein SIX1
expression. FEBS Open Bio. 8:189–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia X, Wen Z, Sun Q, Zhao X, Yang H, Shi X
and Xin T: Apatinib suppresses the proliferation and apoptosis of
gastric cancer cells via the PI3K/Akt signaling pathway. J BUON.
24:1985–1991. 2019.PubMed/NCBI
|
|
30
|
Shang HS, Lu HF, Lee CH, Chiang HS, Chu
YL, Chen A, Lin YF and Chung JG: Quercetin induced cell apoptosis
and altered gene expression in AGS human gastric cancer cells.
Environ Toxicol. 33:1168–1181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang J, Xing L, Xu H, Wang K, She J, Shi
F, Wu H, Sun Y, Gao J and He S: miR-204-5p suppress lymph node
metastasis via regulating CXCL12 and CXCR4 in gastric cancer. J
Cancer. 11:3199–3206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Zhang H, Ge S, Fan Q, Zhou L, Li
H, Bai M, Ning T, Liu R, Wang X, et al: Effects of miR1385p and
miR2045p on the migration and proliferation of gastric cancer cells
by targeting EGFR. Oncol Rep. 39:2624–2634. 2018.PubMed/NCBI
|
|
33
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fanotto V, Ongaro E, Rihawi K, Avallone A,
Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G,
et al: HER-2 inhibition in gastric and colorectal cancers: Tangible
achievements, novel acquisitions and future perspectives.
Oncotarget. 7:69060–69074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Begnami MD, Fukuda E, Fregnani JH,
Nonogaki S, Montagnini AL, da Costa WL Jr and Soares FA: Prognostic
implications of altered human epidermal growth factor receptors
(HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor
outcome. J Clin Oncol. 29:3030–3036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Di Oto E, Brandes AA, Cucchi MC and
Foschini MP: Prognostic impact of HER-2 Subclonal Amplification in
breast cancer. Virchows Arch. 471:313–319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oke OW, Carla L; Gregor and Mariana
Chavez-Mac: Outcomes related to delayed initiation of anti-HER 2
therapy in pregnant HER2 positive breast cancer patients. 53rd
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).
2017.
|
|
38
|
Shabbir A, Qureshi MA, Mirza T and Khalid
AB: Human epidermal growth factor (Her-2) in gastric and colorectal
adenocarcinoma. J Pak Med Assoc. 67:1085–1090. 2017.PubMed/NCBI
|
|
39
|
Sun G, Sun L, Liu Y, Xing H and Wang K:
Her-2 expression regulated by downregulation of miR-9 and which
affects chemotherapeutic effect in breast cancer. Cancer Gene Ther.
24:194–202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao D, Sui Y and Zheng X: miR-331-3p
inhibits proliferation and promotes apoptosis by targeting HER2
through the PI3K/Akt and ERK1/2 pathways in colorectal cancer.
Oncol Rep. 35:1075–1082. 2016. View Article : Google Scholar : PubMed/NCBI
|
